ClinicalTrials.gg
RecruitingNCT04255602TIGERUpdated Dec 7, 2023

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

A Phase 4 interventional study of Ticagrelor 60mg and Ticagrelor 90mg in Acute Coronary Syndrome and Coronary Stent Implantation, sponsored by Shanghai Tong Ren Hospital. Recruiting at 8 sites in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-12-07.

Sponsored by Shanghai Tong Ren Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Planned enrollment
10th of 67
2,120 · median 120
Started
2020
with 3 others
Phase 4
38 of 67
5 open now
Registered
55th of 67
by date
Lead sponsor
3 of 67
Shanghai Tong Ren Hospital

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 10th largest by planned enrollment, is one of 4 that started in 2020, is one of 38 in phase 4, and was the 55th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

03

Conditions studied

  • Acute Coronary Syndrome
  • Coronary Stent Implantation
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 18 years of age
  2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome
  3. Subject understand the study requirements and the treatment procedures and provided before the procedure

Exclusion criteria

Exclusion Criteria:

  1. Female of , unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
  2. Active bleeding
  3. Known or to study medications
  4. Non-cardiac co-morbid conditions are present with \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
  5. Subjects with Cerebral hemorrhage history
  6. Subjects with stroke history in half a year
  7. subjects with malignant tumor
  8. subjects with whom oral anticoagulants are needed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,120 participants (estimated)

Study arms

  • Experimental
    low dose ticagrelor

    After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation

    Drug: Ticagrelor 60mg

  • Active comparator
    standard dose ticagrelor

    subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation

    Drug: Ticagrelor 90mg

Interventions

06

What researchers measure

Primary outcomes

  1. a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis,coronary revascularization,stroke, and bleeding events of BARC grade ≥2

    a composite of death from coronary vascular causes,non-fatal myocardial infarction,stent thrombosis,coronary revascularization, stroke and bleeding type 2, 3 or 5 according to the Bleeding Academic Research Consortium (BARC) criteria

    Time frame: Stent implantation to 12 months

Secondary outcomes

  1. bleeding events of BARC grade ≥2

    bleeding type 2, 3 or 5 according to the Bleeding Academic Research Consortium (BARC) criteria

    Time frame: Stent implantation to 12 months

  2. a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis,coronary revascularization,stroke

    a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis,coronary revascularization,stroke

    Time frame: Stent implantation to 12 months

07

Study locations

4 of 8 sites recruiting
  • Taishan people's hospital
    Taishan, Guangdong 529200, China
    Recruiting
    • yan Chen, Doctor · Contact
    • yan chen, Doctor · Principal investigator
  • South East of Shandong hospital
    Liaocheng, Shandong, China
    Recruiting
    • zhongwei Jia, doctor · Contact
  • zhangshan hospital, Fudan University
    Shanghai, Shanghai 200032, China
    Not yet recruiting
    • Junbo Ge, Doctor · Contact
    • Junbo Ge, Doctor · Principal investigator
  • shanghai Tongren hospital
    Shanghai, Shanghai 200050, China
    Recruiting
    • Lei Hou, Doctor · Contact
    • Lei Hou, Doctor · Principal investigator
    • Caohui Qiu, Doctor · Principal investigator
    • Yanan Peng, Doctor · Sub investigator
  • Minhang hospital, Fudan University
    Shanghai, Shanghai 201100, China
    Not yet recruiting
    • Wei Hu, Doctor · Contact
    • Wei Hu, Doctor · Principal investigator
  • Songjiang hospital, Shanghai jiaotong university, school of medicine
    Shanghai, Shanghai, China
    Not yet recruiting
    • Lei Hou, Dr · Contact
  • Ningbo 4th hospital
    Xiangshan, Zhejiang, China
    Recruiting
    • jianfei Ye, master · Contact
  • Yanzhou branch of affiliated hospital of Jining medical university
    Jining, China
    Not yet recruiting
    • Jian Yang · Contact
08

References and documents

Publications

  • Pang Y, Ma M, Xia J, Wang D, YanChen, Ye J, Jia Z, Wu S, Yang J, Hou L. A randomized non-inferiority study of low-dose and standard-dose ticagrelor after intervention for acute coronary syndrome: study protocol for the TIGER STUDY. Trials. 2022 Mar 5;23(1):203. doi: 10.1186/s13063-022-06124-z. PubMed 35248132 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2024, 58 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 58 months is above that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Feb 5, 2020
StartActual
Feb 19, 2020
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Dec 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04255602
Lead sponsor
Shanghai Tong Ren Hospital
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Feb 19, 2020
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Dec 7, 2023

Study contacts

Lei Hou, Doctor
Contact
Dr_houlei@163.com
13564868096
Junbo Ge, Doctor
Contact
Ge.junbo@zs-hospital.sh.cn
Junbo Ge, Doctor
study chair · Fudan University
Lei Hou, Doctor
principal investigator · Shanghai Tongren Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion